PTGX

Protagonist Therapeutics Inc

PTGX, USA

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

https://www.protagonist-inc.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PTGX
stock
PTGX

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High - What's Next? MarketBeat

Read more →
PTGX
stock
PTGX

Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$90.6923

Analyst Picks

Strong Buy

5

Buy

4

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

130.23

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

9.42

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-6.09 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-5.61 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-42.98 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 107.74% of the total shares of Protagonist Therapeutics Inc

1.

BlackRock Inc

(15.48%)

since

2025/06/30

2.

Farallon Capital Management, L.L.C.

(9.921%)

since

2025/06/30

3.

RTW INVESTMENTS, LLC

(9.2528%)

since

2025/06/30

4.

Vanguard Group Inc

(7.0061%)

since

2025/06/30

5.

iShares Core S&P Small-Cap ETF

(5.9291%)

since

2025/08/31

6.

Deep Track Capital, LP

(5.2175%)

since

2025/06/30

7.

Bvf Inc

(5.1615%)

since

2025/06/30

8.

State Street Corp

(5.1559%)

since

2025/06/30

9.

UBS Group AG

(4.0206%)

since

2025/06/30

10.

Johnson & Johnson

(3.9369%)

since

2025/06/30

11.

Vanguard Total Stock Mkt Idx Inv

(3.1182%)

since

2025/07/31

12.

Geode Capital Management, LLC

(2.3215%)

since

2025/06/30

13.

iShares Russell 2000 ETF

(2.2521%)

since

2025/08/31

14.

Adage Capital Partners Gp LLC

(1.7557%)

since

2025/06/30

15.

COMMODORE CAPITAL LP

(1.728%)

since

2025/06/30

16.

Perceptive Advisors LLC

(1.7271%)

since

2025/06/30

17.

Wellington Management Company LLP

(1.6681%)

since

2025/06/30

18.

SPDR® S&P Biotech ETF

(1.5802%)

since

2025/08/31

19.

ADAR1 Capital Management LLC

(1.5239%)

since

2025/06/30

20.

Woodline Partners LP

(1.522%)

since

2025/06/30

21.

T. Rowe Price Associates, Inc.

(1.5057%)

since

2025/06/30

22.

T. Rowe Price Health Sciences

(1.4191%)

since

2025/07/31

23.

Morgan Stanley - Brokerage Accounts

(1.3968%)

since

2025/06/30

24.

Bank of America Corp

(1.3693%)

since

2025/06/30

25.

Jefferies Financial Group Inc

(1.3245%)

since

2025/06/30

26.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0699%)

since

2025/07/31

27.

Fidelity Small Cap Index

(0.9391%)

since

2025/06/30

29.

iShares S&P Small-Cap 600 Growth ETF

(0.8573%)

since

2025/08/31

30.

iShares Russell 2000 Growth ETF

(0.8233%)

since

2025/08/31

31.

Fidelity Select Biotechnology

(0.7668%)

since

2025/07/31

32.

Vanguard Tax-Managed Small Cap Adm

(0.655%)

since

2025/07/31

33.

BlackRock Health Sciences Opps Inv A

(0.653%)

since

2025/07/31

34.

American Century Small Cap Growth Inv

(0.5969%)

since

2025/06/30

35.

American Century U.S. Small Cap Growth

(0.5969%)

since

2025/06/30

36.

iShares Biotechnology ETF

(0.559%)

since

2025/08/31

37.

Pictet-Biotech P USD

(0.5515%)

since

2025/05/31

38.

Fidelity Extended Market Index

(0.5394%)

since

2025/07/31

39.

SPDR® S&P 600 Small Cap Growth ETF

(0.4848%)

since

2025/08/31

40.

Schwab US Small-Cap ETFâ„¢

(0.4729%)

since

2025/08/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.62

EPS Estimate

-0.6133

EPS Difference

-0.0067

Surprise Percent

-1.0925%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.